mlsanityData to 7 Oct 2026

An artificial intelligence framework for end-to-end rare disease phenotyping from clinical notes using large language models

arXiv 2602.20324 ↗First posted 23 Feb 2026cs.AI cs.CL cs.LGcited by 0

Not on the map. Why?

Abstract (arXiv)

Phenotyping is fundamental to rare disease diagnosis, but manual curation of structured phenotypes from clinical notes is labor-intensive and difficult to scale. Existing artificial intelligence approaches typically optimize individual components of phenotyping but do not operationalize the full clinical workflow of extracting features from clinical text, standardizing them to Human Phenotype Ontology (HPO) terms, and prioritizing diagnostically informative HPO terms. We developed RARE-PHENIX, an end-to-end AI framework for rare disease phenotyping that integrates large language model-based phenotype extraction, ontology-grounded standardization to HPO terms, and supervised ranking of diagnostically informative phenotypes. We trained RARE-PHENIX using data from 2,671 patients across 11 Undiagnosed Diseases Network clinical sites, and externally validated it on 16,357 real-world clinical notes from Vanderbilt University Medical Center. Using clinician-curated HPO terms as the gold standard, RARE-PHENIX consistently outperformed a state-of-the-art deep learning baseline (PhenoBERT) across ontology-based similarity and precision-recall-F1 metrics in end-to-end evaluation (i.e., ontology-based similarity of 0.70 vs. 0.58). Ablation analyses demonstrated performance improvements with the addition of each module in RARE-PHENIX (extraction, standardization, and prioritization), supporting the value of modeling the full clinical phenotyping workflow. By modeling phenotyping as a clinically aligned workflow rather than a single extraction task, RARE-PHENIX provides structured, ranked phenotypes that are more concordant with clinician curation and has the potential to support human-in-the-loop rare disease diagnosis in real-world settings.

Key facts. No citing papers in the map yet (data through 7 Oct 2026). Builds on 18 of its 69 references that are in the map. First posted on arXiv 23 Feb 2026.

Builds on

18 of 69 references.

References · 18

  1. 2023LLaMA: Open and Efficient Foundation Language Modelscited by 13,958
  2. 2020Retrieval-Augmented Generation for Knowledge-Intensive NLP Taskscited by 9,160
  3. 2016XGBoost: A Scalable Tree Boosting Systemcited by 5,120
  4. 2023Instruction Tuning for Large Language Models: A Surveycited by 617
  5. 2025An Agentic System for Rare Disease Diagnosis with Traceable Reasoningcited by 50
  6. 2023Identifying and Extracting Rare Disease Phenotypes with Large Language Modelscited by 18
  7. 2023Enhancing Phenotype Recognition in Clinical Notes Using Large Language Models: PhenoBCBERT and PhenoGPTcited by 17
  8. 2021The RareDis corpus: a corpus annotated with rare diseases, their signs and symptomscited by 11
  9. 2023Large Language Models with Retrieval-Augmented Generation for Zero-Shot Disease Phenotypingcited by 11
  10. 2020PhenoTagger: A Hybrid Method for Phenotype Concept Recognition using Human Phenotype Ontologycited by 9
  11. 2023An evaluation of GPT models for phenotype concept recognitioncited by 9
  12. 2024Information Extraction from Clinical Notes: Are We Ready to Switch to Large Language Models?cited by 9
6 more
  1. 2022Ontology-Driven and Weakly Supervised Rare Disease Identification from Clinical Notescited by 7
  2. 2024A Hybrid Framework with Large Language Models for Rare Disease Phenotypingcited by 7
  3. 2025Integrating Chain-of-Thought and Retrieval Augmented Generation Enhances Rare Disease Diagnosis from Clinical Notescited by 7
  4. 2021Exploring deep learning methods for recognizing rare diseases and their clinical manifestations from textscited by 6
  5. 2025A Specialized Large Language Model for Clinical Reasoning and Diagnosis in Rare Diseasescited by 3
  6. 2025A Weakly Supervised Transformer for Rare Disease Diagnosis and Subphenotyping from EHRs with Pulmonary Case Studiescited by 1

Built on by

Not cited yet.